1
|
Zhang J, Zhang M, Liang Y, Liu M, Huang Z. Downregulation of Smad4 expression confers chemoresistance against imatinib mesylate to chronic myeloid leukemia K562 cells. Hematology 2021; 27:43-52. [PMID: 34957936 DOI: 10.1080/16078454.2021.2010331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
Objective: Imatinib mesylate (IM), a tyrosine kinase inhibitor, exhibits clinically prominent effects against chronic myeloid leukemia (CML); however, a few patients have shown resistance to IM treatment, resulting in disease progression. Smad4 is a tumor inhibitor that transduces TGF-β signaling and modulates genomic stability. Previous studies have indicated that decreased Smad4 expression played a bidirectional role in chemosensitivity in many types of cancers. Therefore, this study aims to evaluate the association between IM sensitivity and decreased Smad4 expression in human CML K562 cells.Methods: Bone marrow (BM) samples were acquired from the patients prior to treatment. qRT-PCR, Western Blotting (WB), colony formation assay (CFA), and apoptosis assay were used to detect relevant indices.Results: Smad4 expression was downregulated in the bone marrow and plasma of patients with multidrug-resistant CML as well as IM-resistant K562 (K562R) cells compared with samples collected from CML patients and K562 cells. Smad4 overexpression inhibited IM-treated K562R cell proliferation and augmented apoptosis, whereas Smad4 silencing promoted viability and inhibited apoptosis in IM-treated K562 cells. In addition, Smad4 expression was inversely correlated with laminin subunit gamma 1 (LAMC1) expression. The upregulation or downregulation of LAMC1 expression partially abolished the effect of Smad4 overexpression or silencing on the IM resistance of CML cells.Conclusion: The downregulation of Smad4 expression might induce drug resistance in CML cells and displayed a possible mechanism through which Smad4 modulates CML cell survival and apoptosis upon IM treatment.
Collapse
Affiliation(s)
- Jiangzhao Zhang
- Department of Hematology, Jingzhou Central Hospital, Institute of Hematology, Yangtze University, Jingzhou, People's Republic of China
| | - Min Zhang
- Department of Nephrology, Jingzhou Central Hospital, Jingzhou, People's Republic of China
| | - Yan Liang
- Department of Hematology, Jingzhou Central Hospital, Jingzhou, People's Republic of China
| | - Min Liu
- Department of Hematology, Jingzhou Central Hospital, Jingzhou, People's Republic of China
| | - Zhiping Huang
- Department of Hematology, Jingzhou Central Hospital, Institute of Hematology, Yangtze University, Jingzhou, People's Republic of China
| |
Collapse
|
2
|
Zuo Y, Lu Y, Xu Q, Sun D, Liang X, Li X, Li Y. Inhibitory effect of dihydromyricetin on the proliferation of JAR cells and its mechanism of action. Oncol Lett 2020; 20:357-363. [PMID: 32565961 PMCID: PMC7286138 DOI: 10.3892/ol.2020.11546] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2019] [Accepted: 03/05/2020] [Indexed: 12/21/2022] Open
Abstract
Dihydromyricetin (DMY) is a novel natural drug with antitumor activity against some cancer cells without obvious toxicity. Previously, its apoptotic effect on human choriocarcinoma was detected. The present study further investigated the therapeutic potential of DMY as a new drug for the treatment of choriocarcinoma, as well as its anti-proliferative effect and mechanism of action. The short-term proliferation of JAR cells was determined by MTT assay, whereas the effect of DMY on long-term cell proliferation was determined by colony forming assay. Flow cytometry was used to detect changes in the cell cycle. Furthermore, western blotting was used to detect the expression levels of proliferation-associated proteins such as cyclin A1, cyclin D1, SMAD3 and SMAD4. Reverse transcription-quantitative PCR (RT-qPCR) was used to quantify mRNA expression levels. The results indicated that DMY inhibited short and long-term proliferation of JAR cells in a concentration-dependent manner. Flow cytometry demonstrated S/G2/M cell cycle arrest, and western blotting revealed the downregulation of SMAD3, SMAD4, cyclin A1 and cyclin D1 expression levels. The results of RT-qPCR and western blotting were consistent. Overall, the findings of the present study suggest that DMY inhibits the proliferation of human choriocarcinoma JAR cells, potentially through cell cycle arrest via the downregulation of cyclin A1, cyclin D1, SMAD3 and SMAD4 expression levels.
Collapse
Affiliation(s)
- Yanzhen Zuo
- Department of Pharmacology, Chengde Medical University, Chengde, Hebei 067000, P.R. China
| | - Yanjie Lu
- Department of Pathology, Chengde Medical University, Chengde, Hebei 067000, P.R. China
| | - Qian Xu
- Research Laboratory, Chengde Medical University, Chengde, Hebei 067000, P.R. China
| | - Dayong Sun
- Department of Tumor Radiation and Chemotherapy Center, Chengde Central Hospital, Chengde, Hebei 067000, P.R. China
| | - Xiujun Liang
- Research Laboratory, Chengde Medical University, Chengde, Hebei 067000, P.R. China
| | - Xiaoru Li
- Department of Gynaecology, Chengde Central Hospital, Chengde, Hebei 067000, P.R. China
| | - Yuhong Li
- Department of Pathology, Chengde Medical University, Chengde, Hebei 067000, P.R. China
| |
Collapse
|
3
|
Jiang L, Sun Y, Wang J, He Q, Chen X, Lan X, Chen J, Dou QP, Shi X, Liu J. Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma. J Exp Clin Cancer Res 2019; 38:453. [PMID: 31694672 PMCID: PMC6836452 DOI: 10.1186/s13046-019-1446-y] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2019] [Accepted: 10/13/2019] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND The first line therapy for patients with diffuse large B cell (DLBCL) is R-CHOP. About half of DLBCL patients are either refractory to, or will relapse, after the treatment. Therefore, identifying novel drug targets and effective therapeutic agents is urgently needed for improving DLBCL patient survival. b-AP15, a selective small molecule inhibitor of proteasomal USP14 and UCHL5 deubiquitinases (DUBs), has shown selectivity and efficacy in several other types of cancer cells. This is the first study to report the effect of b-AP15 in DLBCL. METHODS Cell lines of two DLBCL subtypes, Germinal Center B Cell/ GCB (SU-DHL-4, OCI-LY-1, OCI-LY-19) and Activated B Cell/ABC (SU-DHL-2), were used in the current study. Cell viability was measured by MTS assay, proliferation by trypan blue exclusion staining assay, cellular apoptosis by Annexin V-FITC/PI staining and mitochondrial outer membrane permeability assays, the activities of 20S proteasome peptidases by cleavage of specific fluorogenic substrates, and cell migration was detected by transwell assay in these GCB- and ABC-DLBCL cell lines. Mouse xenograft models of SU-DHL-4 and SU-DHL-2 cells were used to determine in vivo effects of b-AP15 in DLBCL tumors. RESULTS b-AP15 inhibited proteasome DUB activities and activated cell death pathway, as evident by caspase activation and mitochondria apoptosis in GCB- and ABC- DLBCL cell lines. b-AP15 treatment suppressed migration of GCB- and ABC-DLBCL cells via inhibiting Wnt/β-catenin and TGFβ/Smad pathways. Additionally, b-AP15 significantly inhibited the growth of GCB- and ABC DLBCL in xenograft models. CONCLUSIONS These results indicate that b-AP15 inhibits cell migration and induces apoptosis in GCB- and ABC-DLBCL cells, and suggest that inhibition of 19S proteasomal DUB should be a novel strategy for DLBCL treatment.
Collapse
Affiliation(s)
- Liling Jiang
- Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation State Key Laboratory of RespiratoryDisease, School of Basic Medical Science, Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong China
| | - Yuening Sun
- Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation State Key Laboratory of RespiratoryDisease, School of Basic Medical Science, Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong China
| | - Jinxiang Wang
- Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation State Key Laboratory of RespiratoryDisease, School of Basic Medical Science, Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong China
| | - Qingyan He
- Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation State Key Laboratory of RespiratoryDisease, School of Basic Medical Science, Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong China
| | - Xinmei Chen
- Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation State Key Laboratory of RespiratoryDisease, School of Basic Medical Science, Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong China
| | - Xiaoying Lan
- Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation State Key Laboratory of RespiratoryDisease, School of Basic Medical Science, Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong China
| | - Jinghong Chen
- Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation State Key Laboratory of RespiratoryDisease, School of Basic Medical Science, Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong China
| | - Q. Ping Dou
- Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation State Key Laboratory of RespiratoryDisease, School of Basic Medical Science, Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong China
- The Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, and Departments of Oncology, Pharmacology and Pathology, School of Medicine, Wayne State University, Detroit, MI USA
| | - Xianping Shi
- Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation State Key Laboratory of RespiratoryDisease, School of Basic Medical Science, Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong China
- Sino-French Hoffmann institute, Guangzhou Medical University, Guangzhou, China
| | - Jinbao Liu
- Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation State Key Laboratory of RespiratoryDisease, School of Basic Medical Science, Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong China
| |
Collapse
|